Dendreon, aktuell einer der heissesten Werte

http://www.fool.com/investing/general/2008/10/29/...nster-stocks.aspx

durch Click auf die Titelzeile. So ergibt sich ein interessantes Bild. Interessant, wer sich hier offensichtlich gegen Ende des 4. Quartals 08 eingekauft oder zugekauft hat.

Stuttgart 4,69 €,
Nasd "after hour" 6,40 $  ??????

Irgendwas im Busch, technisch bedingt????  

 

dem Options-Verfallstag zusammen, nichts Fundamentales.  

http://newworldinvestor.com/date/2009/02/

Biotech MegaShift

Dendreon (DNDN) gave a presentation at the BIO Conference this week, and addressed the rumors that because the final Provenge Phase III study was terminated earlier than expected because it hit the termination point of 304 deaths, Provenge is likely to fail. On the contrary, early termination probably means Provenge succeeded. In a post on the website, I explained why it was more likely than not that this was good news for Dendreon. In their BIO presentation, this was the key slide:

 

Source: Dendreon

 

In all the earlier trials added together, Provenge achieved a 22% risk reductions in the level of deaths at 24 months, and went on to hit 33% at 36 months. That’s a 50% or 11 percentage point improvement. In this trial, they achieved a 20% reduction at the interim peek and need to pick up only two percentage points to hit 22%–a 10% improvement. I think they’ll get it. Buy DNDN up to $8 for my $40 target after Provenge is approved.

 

 

Nach MFFAIS, kauften letzte Woche folgende Investoren:

BAM Capital verdoppelte Position um 100% - Kauf von 5M shares.

UBS Kauf 1M shares.

Barclays Kauf von fast 900 000 shares.

http://www.mffais.com/dndn.html  

 

http://shortsqueeze.com/?symbol=dndn

Dendreon Corp. $ 3.65 DNDN -0.12

Short Interest (Shares Short) 15,171,500 Days To Cover (Short Interest Ratio) 5.7 Short Percent of Float 16.34 % Short Interest - Prior 17,778,700 Short % Increase / Decrease -14.66 % Short Squeeze Ranking™ -31

% From 52-Wk High ($ 10.00 ) -173.97 % % From 52-Wk Low ($ 3.26 ) 10.68 % % From 200-Day MA ($ 4.97 ) -36.16 % % From 50-Day MA ($ 4.01 ) -9.86 % Price % Change (52-Week) -33.60 %

Shares Float 92,870,000 Total Shares Outstanding 96,941,340 % Owned by Insiders 10.37 % % Owned by Institutions 36.30 % Market Cap. $ 353,835,891 Trading Volume - Today 1,287,433 Trading Volume - Average 2,652,600 Trading Volume - Today vs. Average 48.53 % Earnings Per Share -1.02 PE Ratio   Record Date 2009-FebA

Sector Healthcare Industry Biotechnology Exchange NAS Data Provided Without Warranty

 

ausgeshortet (bei biotechs ist das meistens profitabel, aber eben auch russisch roulette) - dndn kann bis Mitte Mai noch zur gap-Unterkante bei ~13 steigen.  

da geht es richtig ab.